Introduction. The pathogenesis of atopic dermatitis includes genetic predisposition, epidermal barrier dysfunction, immunologic abnormalities and increased immunoglobulin E levels in some of the patients. Objective. Determination the allergen-specific immunoglobulin E level and serum interleukin-33 concentration in patients with atopic dermatitis. Material and methods. The study included 62 patients with atopic dermatitis at the mean age of 30.4 ±11.6 years. Clinical eveluation of the SCORAD index and the objective SCORAD (oSCORAD) was performed. Serum samples were analyzed for immunoglobulin E specific allergy using immunoblot kits for 21 allergens of atopy. Serum concentration of interleukin-33 was examined by ELISA. Results. The SCORAD index was higher (p < 0.05) in atopic dermatitis patients with immunoglobulin E specific to birch, dog fur, horse fur, Cladosporium herbarum, egg white, hazelnut, carrot, and potato than in those without such allergen-specific immunoglobulin E. Objective SCORAD was increased (p < 0.05) in atopic dermatitis patients with immunoglobulin E specific to birch, dog fur, Cladosporium herbarum, egg white, hazelnut, carrot, and potato in comparison to those without such allergen-specific immunoglobulin E. Mean serum concentration of interleukin-33 in patients with atopic dermatitis was 4.9 ±8.12 pg/ml. Serum interleukin-33 level did not correlate with such clinical parameters as the extent of skin lesions, pruritus, sleep disorders, SCORAD index and objective SCORAD. Interleukin-33 level was not higher in atopic dermatitis patients with immunoglobulin E specific to any examined antigen in comparison to those without such immunoglobulin E. Conclusions. Our study suggests that interleukin-33 is not a reliable marker of activity in atopic dermatitis. Further studies are necessary to confirm this hypothesis. StRESzczEniE Wprowadzenie. Patogeneza atopowego zapalenia skóry obejmuje predyspozycje genetyczne, dysfunkcję bariery naskórkowej, nieprawidłowości immunologiczne oraz podwyższony poziom immunoglobulin E u części pacjentów.